FATE THERAPEUTICS INC (FATE)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for FATE
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| FATE | Director Nominee | 61 | [] | [] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| JAZZ | Director, BB Biotech AG | 61 | ["Over 35 years of commercial expertise in the biopharmaceutical industry","Various executive leadership positions in the U.S. and internationally","Former Executive Vice President, Worldwide Commercial Operations at Gilead Sciences, Inc.","Senior Vice President, U.S. Commercial Operations at Amgen Inc.","Consultant for Launch Therapeutics, Inc.","Board member of several biopharmaceutical companies"] | ["Audit Committee","Compensation Committee"] | 2026 |
| ANAB | Director | 56 | [] | [] | 2021 |
Biography sourced from the proxy statement filing.
Laura J. Hamill has served on the board of directors of BB Biotech, a Swiss-based investment fund, since March 2022, and Jazz Pharmaceuticals Public Limited Company (Nasdaq: JAZZ), since July 2024. Ms. Hamill also serves on the board of directors of Unchained Labs, a privately-held life sciences tools company. Ms. Hamill previously served on the boards of directors of the following biopharmaceutical companies: Y-mAbs Therapeutics, Inc. (formerly Nasdaq: YMAB, acquired by SERB Pharmaceuticals), from June 2020 to September 2025, Acceleron Pharma Inc. (formerly Nasdaq: XLRN, acquired by Merck & Co., Inc.) from September 2020 to November 2021, AnaptysBio, Inc. (Nasdaq: ANAB) from September 2019 to April 2023, Pardes Biosciences, Inc. (formerly Nasdaq: PRDS, acquired by MediPacific, Inc.) from July 2021 to August 2023 and Scilex Holding Company (Nasdaq: SCLX) from November 2022 to September 2023. Ms. Hamill held the position of Executive Vice President, Worldwide Commercial Operations, for Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company, from 2018 to 2019. From 2002 to 2018, Ms. Hamill served in various executive management positions at Amgen Inc. (Nasdaq: AMGN), a global biotechnology company, culminating in her role as Senior Vice President, U.S. Commercial Operations. She has extensive experience living and working overseas for Amgen with responsibilities for the overall product portfolio. She was Head of International Marketing and Business Operations, in Zug, Switzerland and also served as Senior Vice President of Amgen s Intercontinental Region, consisting of 26 countries. She was Vice President and General Manager for the Inflammation Business Unit at Amgen and Immunex Corporation (acquired by Amgen) from 2000 to 2007. From 1995 to 2000, Ms. Hamill held senior management positions at Klemtner, a biopharmaceutical advertising agency and, from 1988 to 1995, started her career in pharmaceuticals with Hoffmann La-Roche Laboratories holding positions in product management, business analysis and field sales. Ms. Hamill holds a degree in Business Administration with an emphasis in Marketing from the University of Arizona. The Board of Directors has determined that Ms. Hamill is qualified to serve on our Board of Directors due to her having over 35 years of commercial expertise in the biopharmaceutical industry, having held a variety of executive leadership positions in the United States and internationally.